Status:
COMPLETED
Kidney Damage in Patients With Normal eGFR
Lead Sponsor:
Bracco Diagnostics, Inc
Conditions:
Coronary Artery Stenosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal...
Eligibility Criteria
Inclusion
- Provides written Informed Consent and is willing to comply with protocol requirements;
- Is at least 18 years of age;
- Is scheduled to undergo a percutaneous coronary intervention and/or diagnostic coronary angiography.
- Has documented estimated glomerular filtration rate \[eGFR\] ≥60 mL/min/1.73 m2 calculated with the MDRD formula within 72 hours prior to enrollment.
Exclusion
- Is a pregnant or lactating female.
- Has a history of severe congestive heart failure
- Has a history of hyperthyroidism
- Has a history of hypersensitivity to iodinated contrast agents
- Has unstable renal function
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT01137786
Start Date
December 1 2010
End Date
April 1 2012
Last Update
September 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prairie Cardiovascular Consultants, Ltd.
Springfield, Illinois, United States, 62701